Compugen Announces Addition of Prof. Drew Pardoll to Its Scientific Advisory Board
January 21 2014 - 7:00AM
Business Wire
Prof. Pardoll is a world leader in
immuno-oncology research and in the development of novel cancer
therapeutics
Compugen Ltd. (NASDAQ: CGEN) announced today that Drew Pardoll,
MD, PhD, Abeloff Professor of Oncology, Medicine, Pathology, and
Molecular Biology and Genetics at Johns Hopkins University of
Medicine, has joined Compugen’s Scientific Advisory Board (SAB).
The SAB, disclosed in August 2013, provides insight and guidance on
the Company’s activities in the fields of oncology and immunology
with particular emphasis on its early stage pipeline of therapeutic
proteins and monoclonal antibodies, largely based on
Compugen-discovered immune checkpoint protein candidates.
Prof. Pardoll joins Compugen’s SAB, which already consists of
Charles G. Drake, MD, PhD, Associate Professor of Oncology,
Immunology and Urology at Johns Hopkins Kimmel Cancer Center; Iain
B. McInnes, MD, PhD, Director of the Institute of Infection,
Immunity, and Inflammation at the University of Glasgow; Antoni
Ribas, MD, PhD, Professor at the Department of Medicine,
Hematology/Oncology, University of California Los Angeles; and
Howard R. Soule, PhD, Executive Vice President and Chief Science
Officer, Prostate Cancer Foundation.
Anat Cohen-Dayag, PhD, President and CEO of Compugen, stated,
“We are delighted to welcome Prof. Pardoll, a renowned scientist
and key opinion leader in the field of immuno-oncology, to our SAB.
We recently announced an increase of more than sixty percent in our
R&D budget for the current year relative to 2013, primarily in
support of our Pipeline Program candidates in immuno-oncology, and
therefore very much look forward to benefiting from the knowledge
and guidance to be provided by Drew and the other SAB members."
For the past two decades, Prof. Pardoll has studied molecular
aspects of immune regulation, particularly related to mechanisms by
which cancer cells evade elimination by the immune system. Prof.
Pardoll made seminal advances in immunology, including the
discovery of new types of immune cells and regulatory mechanisms.
He was the first to propose blockade of PD-1 for cancer therapy,
and his program led the clinical development of the first anti-PD-1
antibody. Prof. Pardoll is the inventor of a number of
immunotherapies, including cancer vaccines, and was a scientific
founder of Amplimmune Inc. He has served on the editorial boards of
the Journal of the National Cancer Institute and Cancer Cell, and
has been a member of numerous corporate and other scientific
advisory boards. Prof. Pardoll is Director of the Cancer Immunology
Program in the Sydney Kimmel Comprehensive Cancer Center at Johns
Hopkins and completed his MD, PhD, Medical Residency and Oncology
Fellowship at Johns Hopkins University.
About Compugen
Compugen is a leading drug discovery company focused on
therapeutic proteins and monoclonal antibodies to address important
unmet needs in the fields of immunology and oncology. The Company
utilizes a broad and continuously growing integrated infrastructure
of proprietary scientific understandings and predictive platforms,
algorithms, machine learning systems and other computational
biology capabilities for the in silico (by computer) prediction and
selection of product candidates, which are then advanced in its
Pipeline Program. The Company's business model includes
collaborations covering the further development and
commercialization of product candidates at various stages from its
Pipeline Program and various forms of research and discovery
agreements, in both cases providing Compugen with potential
milestone payments and royalties on product sales or other forms of
revenue sharing. In 2012, Compugen established operations in
California for the development of oncology and immunology
monoclonal antibody therapeutic candidates against Compugen drug
targets. For additional information, please visit Compugen's
corporate website at www.cgen.com.
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of
1995. These statements, include words such as “may,” “expects,”
“anticipates,” “potential,” “believes,” and “intends,” and describe
opinions about future events. Forward-looking statements in this
press release include, but are not limited to, statements relating
to future benefits from Prof. Pardoll and other SAB members to
Compugen and the increase in the R&D budget for 2014. These
forward-looking statements involve known and unknown risks and
uncertainties that may cause the actual results, performance or
achievements of Compugen to be materially different from any future
results, performance or achievements expressed or implied by such
forward-looking statements. Some of these risks and other factors
are discussed in the "Risk Factors" section of Compugen’s Annual
Report on Form 20-F for the year ended December 31, 2012 as filed
with the Securities and Exchange Commission. In addition, any
forward-looking statements represent Compugen’s views only as of
the date of this release and should not be relied upon as
representing its views as of any subsequent date. Compugen does not
assume any obligation to update any forward-looking statements
unless required by law.
Compugen Ltd.Tsipi HaitovskyGlobal Media
Liaison+972-52-598-9892tsipih@netvision.net.il
Compugen (NASDAQ:CGEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Compugen (NASDAQ:CGEN)
Historical Stock Chart
From Sep 2023 to Sep 2024